Overcoming Barriers to more Effective Adoptive T Cell Therapies

When:  Dec 13, 2021 from 09:00 to 10:00 (AEST)
Sunday, December 12 - 15:00 PST / 18:00 EST
What time is this for me?

Overcoming Barriers to more Effective Adoptive T Cell Therapies

Lecture 3 of the ISCT ANZ Cell & Gene Therapy Translation Lecture Series
Organized by the ISCT Australia & New Zealand Regional Executive Committee

Lecture Description:

The ISCT ANZ Cell & Gene Therapy Translation Lecture Series aims to provide ISCT members innovative and ground-breaking research in cell and gene therapy. These lectures will be presented by world-leading experts and will focus on cutting edge advances in cell and gene therapy development, manufacturing, and clinical application.

In the third lecture of the series, Professor Stanley Riddell will address the following topics:

- Principles of adoptive cell therapies
- Fundamentals of receptor design and function
- Mechanisms of response and resistance
- Barriers in applying cell therapy to solid tumors

Co-Chaired By: 

Rajiv Khanna, PhD AO
ISCT ANZ Regional Vice-President
QIMR Berghofer Medical Research Institute

Professor Rajiv Khanna obtained his doctorate degree from India and undertook his post-doctoral training at the Queensland Institute of Medical Research (QIMR). He is the Coordinator of QIMR Berghofer Centre for Immunotherapy and Vaccine Development. He holds Senior Principal Research Fellowship from the National Health and Medical Research Council of Australia and was also appointed as Honorary Professor at the University of Queensland and Griffith University, Brisbane. Professor Khanna is a Fellow of Australian Academy of Health and Medical Sciences.

Jessica Sue.png

Jessica Sue, MSc, MHSM
ISCT ESP Committee Member
Sydney Cord Blood Bank

Jessica Sue is the Quality Manager at the Sydney Cord Blood Bank, and in this role is responsible for the overall management of the quality system at the facility. She has experience in the regulatory requirements of cellular therapy organisations, particularly in the cord blood banking setting. She has been involved in ISCT as a mentee and currently is a member of the global ISCT ESP Committee. She also holds positions on committees with partner organisations such as FACT. 


Stanley Riddell, MD
Fred Hutchinson Cancer Research Center
United States

Dr. Riddell is a Member at the Fred Hutchinson Cancer Research, Professor in the Department of Medicine at the University of Washington, and Distinguished Affiliate Professor at the Technical University of Munich. His research focuses on understanding the contributions of distinct human T cell subsets to protective immunity to pathogens and tumors and on the development and clinical application of adoptive T cell therapy for cancer using unmodified and genetically modified antigen-specific T cells of defined compositions. The work has encompassed the discovery of target antigens and evaluating the adoptive transfer of antigen-specific and genetically engineered T cells to treat human diseases.